<DOC>
	<DOC>NCT00632931</DOC>
	<brief_summary>A 2-period, crossover study to assess the effects of MK0683 (vorinostat) on the QTc interval in patients with relapsed or refractory advanced cancer.</brief_summary>
	<brief_title>A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)</brief_title>
	<detailed_description>Merck Duration of Treatment : vorinostat; treatment will continue until disease progression or intolerable toxicity is reached</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patient has a histologicallyconfirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy or for which standard therapy does not exist Patient has life expectancy of greater than 3 months Patient is able to swallow capsules Patient has had chemotherapy, radiotherapy or biological therapy 2 weeks prior to taking study drug Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent Patient has active CNS metastases and/or carcinomatous meningitis Patient has primary central nervous system tumor Patient has a history of drug or alcohol abuse Patient has Hepatitis B or C Patient is HIV positive Patient has active infection or has received intravenous antibiotics, antiviral or antifungal agents 2 weeks before taking study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>